Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aurobindo Seeks To Boost India Business With Veritaz Acquisition

Indian Pharma Firm Has Paid INR1.71bn For Domestic Formulations Business

Executive Summary

Aurobindo is looking to grow its business in India by acquiring Veritaz’s domestic formulations operations in a $22.4m slump sale.

You may also be interested in...



Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf

AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.

What’s Next? Five Things To Look Out For In April

In the month ahead, Japanese firms are set to be hit with further price cuts to their generics, while Eagle Pharmaceuticals will throw off the restraints for its Pemfexy (pemetrexed) 505(b)(2) version of Eli Lilly’s Alimta.

Aurobindo Accelerates Biosimilars Efforts With Second Filing

Aurobindo has filed for its second oncology biosimilar with the EMA in January 2022, as the company remains on track to develop its biosimilars portfolio in both oncology and immunology segments. The company has also launched seven products, including four injectables, in its financial third quarter ended 31 December 2021.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel